Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
TIRZEPATIDE (Mounjaro®) (NEW) Grey Management of overweight and obesity
January 2025: Tirzepatide should NOT be prescribed for managing overweight and obesity. 
Whilst NICE TA1026 was published in December 2024, the ICB awaits further commissioning guidance from NHS England. Further details about local implementation will be provided in due course. Until that time, tirzepatide should not be prescribed for this indication.

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more